Business ProfileforEncore Plus Solutions Inc.

The following describes a pending government action that has been formally brought by a government agency but has not yet been resolved. We are providing a summary of the government's allegations, which have not yet been proven.

As of April 20, 2020, Federal Trade Commission Civil Action No. 1:20-cv-21622-FAM, According to an FTC lawsuit, a group of seven U.S. and Canadian defendants used glossy magazine-style mailers to advertise that Neurocet, Regenify, and Resetigen-D could treat a list of diseases, maladies, and conditions.

The defendants pitched Neurocet as an answer to the kinds of chronic pain that often besets older consumers, including arthritis, back pain, and headaches. What's more, they promised that Neurocet provides relief that lasts 26 times longer than popular pain medications and is even stronger than morphine, leading to reduced inflammation and greater mobility and flexibility. And just to gild the pain relief lily, they said their claims were supported by scientific or clinical proof.

They advertised Regenify and Resetigen-D to repair cell damage everywhere in the body, turning back the clock on damage to skin, tissue, bones, and organs while also improving memory and brain function by as much as 97.4%. That's just for starters. The ads also pitched the products as a treatment for arthritis, tinnitus, asthma, high cholesterol, psoriasis, and eczema. Oh, and users would lose weight and gain muscle.

Ads for Regenify and Resetigen-D featured glowing testimonials from people who had supposedly tried the products. They also trotted out purported endorsements from gastroenterologists, neurologists, nephrologists, pulmonologists, cardiologists, rheumatologists, and pretty much every other kind of -ologist who's ever donned a white coat.

The complaint charges the defendants with making "false or unsubstantiated claims." Others might use stronger language to describe the practice of targeting older consumers in this fashion, especially considering the defendants didn't have scientific support for their representations and used purported endorsements from medical professionals and consumers that were flat-out fictitious.

The proposed stipulated order puts provisions in place to protect consumers in the future and requires the defendants to turn over $1.3 million, which may be used for consumer refunds.

For further assistance please contact:
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, DC 20580
Telephone: (202) 326-2222
https://www.ftc.gov

LINK: https://www.ftc.gov/news-events/blogs/business-blog/2020/04/deceptive-pain-claims-remain-bane?utm_source=govdelivery